BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34000272)

  • 1. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
    Manning JJ; Green HM; Glass M; Finlay DB
    Neuropharmacology; 2021 Aug; 193():108611. PubMed ID: 34000272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational potential of allosteric modulators targeting the cannabinoid CB
    Lu D; Immadi SS; Wu Z; Kendall DA
    Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
    Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
    Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
    Cawston EE; Redmond WJ; Breen CM; Grimsey NL; Connor M; Glass M
    Br J Pharmacol; 2013 Oct; 170(4):893-907. PubMed ID: 23937487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantiomer-specific positive allosteric modulation of CB
    Mitjavila J; Yin D; Kulkarni PM; Zanato C; Thakur GA; Ross R; Greig I; Mackie K; Straiker A
    Pharmacol Res; 2018 Mar; 129():475-481. PubMed ID: 29158048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
    Grey J; Terry P; Higgs S
    Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CB
    Mielnik CA; Lam VM; Ross RA
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110163. PubMed ID: 33152384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.
    Patel M; Finlay DB; Glass M
    Cell Signal; 2021 Feb; 78():109865. PubMed ID: 33259937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
    Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
    Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
    Nguyen T; Li JX; Thomas BF; Wiley JL; Kenakin TP; Zhang Y
    Med Res Rev; 2017 May; 37(3):441-474. PubMed ID: 27879006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Allosteric Modulation of CB
    Scott CE; Kendall DA
    Methods Enzymol; 2017; 593():317-342. PubMed ID: 28750809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.
    Mallipeddi S; Janero DR; Zvonok N; Makriyannis A
    Biochem Pharmacol; 2017 Mar; 128():1-11. PubMed ID: 27890725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
    Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocannabinoids and Their Pharmacological Actions.
    Pertwee RG
    Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of structurally novel G protein biased CB
    Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric modulators restore orthosteric agonist binding to mutated CB
    Dopart R; Kendall DA
    J Pharm Pharmacol; 2020 Jan; 72(1):84-91. PubMed ID: 31722122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.